Alexion Pharmaceuticals (ALXN) Tops Q2 Views; Guides Higher
More News related to ALXN
- Alexion Pharmaceuticals' (ALXN) Keiser to Retire
- David W. Keiser to Retire as President of Alexion
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
- Alexion to Present at Investor Conferences
- David Moenning's Daily State of the Markets: 10/23
More News related to Earnings
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Alexion Pharmaceuticals (Nasdaq: ALXN) reports Q2 earnings of $0.06 per share, above the consensus of a $0.14 loss. Revenues came in at $59.6 million versus the consensus of $54 million.
Sees $235-$245 million versus prior guidance of $215-$225 million and the consensus of $228.4 million.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-3.43Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
